echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > There is another class of new drugs declared in the tablets eager to seize the hepatitis drug market.

    There is another class of new drugs declared in the tablets eager to seize the hepatitis drug market.

    • Last Update: 2020-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 18th, the pharmaceutical network announced that a class of 1 new drug PZH2109 capsules declared clinically received CDE acceptance, the drug is mainly used to treat non-alcoholic fatty hepatitis, the United States and China have no same target of the same adaptive drugs approved for market.
    Figure 1: The declaration of new drugs in type 1 of CDE official website: CDE official website by virtue of three exclusive Chinese medicine tablets, tablets, pills capsules, Yin bile flat liver capsules dominate the retail market for hepatitis Chinese medicine, in recent years, the company in research and development aimed at the chemical drug market, July 1, 2020 New drug PZH2111 tablets declared clinical acceptance, the product is mainly used for the treatment of liver bile tube cell carcinoma, urinary tracheoblast cancer and other advanced solid tumors, the domestic no similar drugs with the same adaptance was approved for the market, MED2.0 China drug review database data show that the current two acceptance numbers are in the review and approval.
    , the company's class 1 new drug PZH2109 capsules declared clinically accepted CDE, the drug is mainly used in the treatment of non-alcoholic fatty hepatitis (NASH).
    has completed the PZH2109 capsule API and preparation of pharmacological, pharmacological toxicology, non-clinical safety evaluation and other aspects of research, the results show that PZH2109 capsule has good safety, drug-making and clinical development value.
    , the drug project has invested about 25 million yuan in research and development.
    it is understood that in March 2020, the saroglitazar magnesium drug NASH was approved for marketing by the Indian Drug Administration (DCGI), and that no drugs with the same targets as this project have been approved for market in the United States and China.
    data show that saroglitazar magnesium is a new type of peroxidase proliferative active receptacle (PPAR) agitant, the world's first approved treatment for non-hepasclerosis NASH drugs.
    According to the company's annual report data show that in 2019, the research and development investment of tablets is close to 120 million yuan, an increase of 18.47 percent year-on-year, in the study of 11 varieties of drugs, involving Traditional Chinese medicine, chemical innovation drugs and generic drugs, in addition to PZH2111, PZH2109, the treatment of widespread anxiety disorders new drug PZH1204 is also worth looking forward to.
    source: CDE official website, in-network database review data statistics as of 17 August 2020, if there are errors, please point out.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.